Recently, several authoritative institutions have noted that new national policies are effectively addressing the reimbursement bottlenecks hindering the clinical adoption of surgical robots. Although surgical robots offer significant advantages—such as high precision, minimally invasive procedures, and faster patient recovery—their widespread use has been limited by the absence of clear medical insurance billing codes and reimbursement pathways. Since 2023, China’s National Healthcare Security Administration and local health commissions have issued guidelines explicitly including certain robot-assisted surgical procedures in the official list of medical services, assigning them dedicated billing codes. Some regions have even launched pilot programs to include these procedures under medical insurance coverage. This policy breakthrough not only enhances accessibility to advanced medical technologies but also boosts the domestic surgical robotics industry. Experts believe that with clearer reimbursement mechanisms, surgical robots are poised to transition from a ‘luxury’ to a standard clinical tool, accelerating their adoption in top-tier hospitals and eventually in primary care settings—ultimately benefiting a broader patient population.
近期，多家权威机构指出，国家相关政策的出台正有效打通手术机器人在临床应用中的收费瓶颈。长期以来，手术机器人虽具备高精度、微创、恢复快等优势，但因缺乏明确的医保收费编码和报销路径，导致医院引进意愿不足、患者使用成本高昂。2023年以来，国家医保局及地方卫健委陆续发布文件，明确将部分手术机器人辅助操作纳入医疗服务项目，并设立独立收费编码，部分地区已将其纳入医保支付试点。这一政策突破不仅有助于提升高端医疗设备的可及性，也推动了国产手术机器人产业的发展。专家认为，随着收费机制的理顺，手术机器人有望从‘高端奢侈品’逐步转变为常规临床工具，加速在三甲医院乃至基层医疗机构的普及应用，最终惠及更多患者。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/20156.html